Definition and Predictors of Early Recurrence in Neoadjuvantly Treated Esophageal and Gastroesophageal Adenocarcinoma: a Dual-Center Retrospective Cohort Study
Early recurrence can be defined as recurrent disease within 18 months. Hallmarks for early recurrence are poor response to neoadjuvant therapy with persisting advanced disease. In those patients, adjuvant therapy and closer follow-up should be considered.
Authors
- Nerma Crnovrsanin (ORCID: https://orcid.org/0009-0006-0036-9897)
- Beat Peter Müller-Stich (ORCID: https://orcid.org/0000-0002-8552-8538)
- Henrik Nienhüser (ORCID: https://orcid.org/0000-0002-0475-9538)
- Kerstin J. Neuschütz
- Adrian T. Billeter (ORCID: https://orcid.org/0000-0001-8724-4793)
- Julian Musa (ORCID: https://orcid.org/0000-0002-9138-1819)
- Ingmar F. Rompen (ORCID: https://orcid.org/0000-0002-0257-1654)
- Leila Sisic (ORCID: https://orcid.org/0000-0003-1260-5771)
- Martin Bolli (ORCID: https://orcid.org/0000-0003-2676-6322)
- Lana Fourie (ORCID: https://orcid.org/0000-0003-4291-4700)
- Marko Kraljević (ORCID: https://orcid.org/0000-0001-5243-6269)
- Mohammed Al‐Saeedi (ORCID: https://orcid.org/0000-0002-0583-4472)
Institutions
- Heidelberg University (DE)
- University Hospital Heidelberg (DE)
- University Hospital of Basel (CH)
- St. Claraspital (CH)
Publication Details
- Journal
- Annals of Surgical Oncology
- Published
- 2024-11-05
- DOI
- https://doi.org/10.1245/s10434-024-16403-5
- Citations
- 9
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 5.15
Funders
- Universität Basel